Skinvisible, Inc. (SKVI) stock
SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.16+0.00 (+0.06%)
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible net income
Net income is the profit left for shareholders after every expense, interest and tax.
Skinvisible's net income for the twelve months ending Jun 30, 2026 was -$1.03M. For fiscal 2025 it was -$1.06M. The highest annual figure on record is $158.34K in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.06M | – |
| FY2024 | Dec 31, 2024 | -$565.65K | – |
| FY2023 | Dec 31, 2023 | -$2.38M | – |
| FY2022 | Dec 31, 2022 | -$1.22M | – |
| FY2021 | Dec 31, 2021 | -$1.07M | – |
| FY2020 | Dec 31, 2020 | -$1.45M | – |
| FY2019 | Dec 31, 2019 | -$1.70M | -1175.0% |
| FY2018 | Dec 31, 2018 | $158.34K | – |
| FY2017 | Dec 31, 2017 | -$1.83M | – |
| FY2016 | Dec 31, 2016 | -$2.05M | – |
| FY2015 | Dec 31, 2015 | -$1.99M | – |
| FY2014 | Dec 31, 2014 | -$1.93M | – |
| FY2013 | Dec 31, 2013 | -$1.34M | – |
| FY2012 | Dec 31, 2012 | -$1.45M | – |
| FY2011 | Dec 31, 2011 | -$1.36M | – |
| FY2010 | Dec 31, 2010 | -$1.07M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$255.53K | – |
| Q1 FY2026 | Mar 31, 2026 | -$267.18K | – |
| Q4 FY2025 | Dec 31, 2025 | -$258.36K | -182.1% |
| Q3 FY2025 | Sep 30, 2025 | -$250.25K | – |
| Q2 FY2025 | Jun 30, 2025 | -$274.43K | – |
| Q1 FY2025 | Mar 31, 2025 | -$281.01K | – |
| Q4 FY2024 | Dec 31, 2024 | $314.77K | – |
| Q3 FY2024 | Sep 30, 2024 | -$286.60K | – |
| Q2 FY2024 | Jun 30, 2024 | -$303.45K | – |
| Q1 FY2024 | Mar 31, 2024 | -$290.37K | – |
| Q4 FY2023 | Dec 31, 2023 | -$303.79K | – |
| Q3 FY2023 | Sep 30, 2023 | -$287.52K | – |
| Q2 FY2023 | Jun 30, 2023 | -$276.08K | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$400.58K | – |
| Q3 FY2022 | Sep 30, 2022 | -$418.07K | – |
| Q4 FY2021 | Dec 31, 2021 | -$165.38K | – |
| Q3 FY2021 | Sep 30, 2021 | -$203.35K | – |
| Q2 FY2021 | Jun 30, 2021 | -$268.51K | – |
| Q1 FY2021 | Mar 31, 2021 | -$435.51K | – |
| Q4 FY2020 | Dec 31, 2020 | -$294.98K | – |
| Q3 FY2020 | Sep 30, 2020 | -$409.76K | – |
| Q2 FY2020 | Jun 30, 2020 | -$312.79K | – |
| Q1 FY2020 | Mar 31, 2020 | -$430.08K | – |
| Q4 FY2019 | Dec 31, 2019 | -$427.28K | – |
| Q3 FY2019 | Sep 30, 2019 | -$348.74K | -154.8% |
| Q2 FY2019 | Jun 30, 2019 | -$583.01K | – |
| Q1 FY2019 | Mar 31, 2019 | -$343.10K | -455.4% |
| Q4 FY2018 | Dec 31, 2018 | -$177.63K | – |
| Q3 FY2018 | Sep 30, 2018 | $636.10K | – |
| Q2 FY2018 | Jun 30, 2018 | -$396.66K | – |
| Q1 FY2018 | Mar 31, 2018 | $96.53K | – |
| Q4 FY2017 | Dec 31, 2017 | -$123.30K | – |
| Q3 FY2017 | Sep 30, 2017 | -$552.27K | – |
| Q2 FY2017 | Jun 30, 2017 | -$672.26K | – |
| Q1 FY2017 | Mar 31, 2017 | -$478.98K | – |
| Q4 FY2016 | Dec 31, 2016 | -$473.57K | – |
| Q3 FY2016 | Sep 30, 2016 | -$483.99K | – |
| Q2 FY2016 | Jun 30, 2016 | -$463.93K | – |
See a number that looks wrong?